Literature DB >> 21509651

Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?

Roland Därr1, Graeme Eisenhofer, Jörg Kotzerke, Klaus Zöphel, Christian Stroszczynski, Jaap Deinum, Leo J Schultze Kool, Steffen Pistorius, Hartmut Neumann, Stefan R Bornstein, Lorenz C Hofbauer.   

Abstract

Our objective is to outline the utility of adrenal venous sampling (AVS) with measurements of metanephrine to normetanephrine ratios for diagnostic localization of phaeochromocytoma in a patient with normal plasma levels of catecholamines. A 53-year-old-woman was referred for evaluation of recurrent pheochromocytoma following a right adrenalectomy 14 years earlier. Diagnosis of recurrent disease was established from elevations in plasma metanephrines with normal levels of catecholamines. Magnetic resonance imaging indicated two 1-2 cm masses in the right surgical bed and another 1-1.5 cm mass in the left adrenal. These masses were negative on (123)I-metaiodobenzylguanidine scintigraphy. There was no evidence of a hereditary syndrome. We, therefore, carried out two investigational approaches to identify the tumor masses. Hybrid positron emission tomography/computed tomography with (68)Ga-DOTATOC ((68)Ga-DOTATOC-PET/CT) confirmed the presence of recurrent disease in the right surgical bed and also suggested additional left adrenal involvement. Normal plasma catecholamines precluded the use of adrenal venous sampling (AVS) with catecholamine measurements. Hence, we performed AVS with measurements of plasma metanephrines, which were 4- to 7-fold higher in the left adrenal vein than in central venous plasma. We observed a reversal of the normally high metanephrine to normetanephrine ratio (mean value ± SD 5.28 ± 1.86; range 3.36-8.84, n = 13) to 0.73, establishing the presence of a left adrenal pheochromocytoma. Surgical pathology confirmed bilateral disease. This case highlights a scenario where a combination of (68)Ga-DOTATOC-PET/CT and AVS with measurement of the metanephrine to normetanephrine ratio was crucial for the preoperative assessment of a patient with bilateral pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21509651     DOI: 10.1007/s12020-011-9471-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  10 in total

1.  Localization of pheochromocytomata by caval catheterization.

Authors:  T S Harrison; J F Seaton; J C Cerny; J J Bookstein; J D Bartlett
Journal:  Arch Surg       Date:  1967-09

2.  A "pheo" lurks: novel approaches for locating occult pheochromocytoma.

Authors:  K Pacak; D S Goldstein; J L Doppman; B L Shulkin; R Udelsman; G Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

3.  SDHD-related chromaffin tumours: disease localisation to genetic dysfunction.

Authors:  U Srirangalingam; B Khoo; M Matson; R Carpenter; R Reznek; E R Maher; S L Chew; W M Drake
Journal:  Horm Res Paediatr       Date:  2010-02-09       Impact factor: 2.852

4.  Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005.

Authors:  Karel Pacak; Graeme Eisenhofer; Håkan Ahlman; Stefan R Bornstein; Anne-Paule Gimenez-Roqueplo; Ashley B Grossman; Noriko Kimura; Massimo Mannelli; Anne Marie McNicol; Arthur S Tischler
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-02

5.  Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines.

Authors:  G Eisenhofer; B Rundquist; A Aneman; P Friberg; N Dakak; I J Kopin; M C Jacobs; J W Lenders
Journal:  J Clin Endocrinol Metab       Date:  1995-10       Impact factor: 5.958

6.  The use of venous catheterization in the diagnosis and localization of bilateral phaeochromocytomas.

Authors:  E C Newbould; G A Ross; J E Dacie; P M Bouloux; G M Besser; A Grossman
Journal:  Clin Endocrinol (Oxf)       Date:  1991-07       Impact factor: 3.478

7.  Catecholamine measurements in phaeochromocytoma: a review.

Authors:  R C Causon; M J Brown
Journal:  Ann Clin Biochem       Date:  1982-11       Impact factor: 2.057

8.  Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results.

Authors:  Graeme Eisenhofer; David S Goldstein; McClellan M Walther; Peter Friberg; Jacques W M Lenders; Harry R Keiser; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].

Authors:  H Hartmann; K Zöphel; R Freudenberg; L Oehme; M Andreeff; G Wunderlich; G Eisenhofer; J Kotzerke
Journal:  Nuklearmedizin       Date:  2009-07-28       Impact factor: 1.379

10.  Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.

Authors:  Esther Korpershoek; Bart-Jeroen Petri; Francien H van Nederveen; Winand N M Dinjens; Albert A Verhofstad; Wouter W de Herder; Sonja Schmid; Aurel Perren; Paul Komminoth; Ronald R de Krijger
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

  10 in total
  3 in total

Review 1.  Mini-review: pheochromocytomas causing the ectopic ACTH syndrome.

Authors:  Chitrabhanu Ballav; Auditi Naziat; Radu Mihai; Niki Karavitaki; Olaf Ansorge; Ashley B Grossman
Journal:  Endocrine       Date:  2012-03-07       Impact factor: 3.633

2.  Pheochromocytoma - update on disease management.

Authors:  Roland Därr; Jacques W M Lenders; Lorenz C Hofbauer; Bernd Naumann; Stefan R Bornstein; Graeme Eisenhofer
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

3.  Adrenal venous catecholamine concentrations in patients with adrenal masses other than pheochromocytoma.

Authors:  Yasutaka Baba; Masayuki Nakajo; Sadao Hayashi
Journal:  Endocrine       Date:  2012-09-13       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.